These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12025888)

  • 1. Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma.
    Puls LE; Hunter JE; Crane MM
    Med Oncol; 2002; 19(1):25-33. PubMed ID: 12025888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.
    Elkas JC; Holschneider CH; Katz B; Li AJ; Louie R; McGonigle KF; Berek JS
    Int J Gynecol Cancer; 2003; 13(2):138-41. PubMed ID: 12657113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
    Morris R; Alvarez RD; Andrews S; Malone J; Bryant C; Heilbrun LK; Smith D; Schimp V; Munkarah A
    Gynecol Oncol; 2008 Jun; 109(3):346-52. PubMed ID: 18410954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
    J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.
    Gore M; Oza A; Rustin G; Malfetano J; Calvert H; Clarke-Pearson D; Carmichael J; Ross G; Beckman RA; Fields SZ
    Eur J Cancer; 2002 Jan; 38(1):57-63. PubMed ID: 11750840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.